Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Acerus Pharmaceuticals Corporation
  6. News
  7. Summary
    ASP   CA00444G1081

ACERUS PHARMACEUTICALS CORPORATION

(ASP)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Acerus Pharmaceuticals Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021

11/08/2021 | 06:00pm EST

Acerus Pharmaceuticals Corporation reported earnings results for the third quarter and nine months ended September 30, 2021. For the third quarter, the company reported revenue was USD 0.587 million compared to USD 0.493 million a year ago. Net loss was USD 4.9 million compared to USD 7.05 million a year ago. For the nine months, negative revenue was USD 4.87 million compared to revenue of USD 0.814 million a year ago. Net loss was USD 24.79 million compared to USD 17.32 million a year ago. Basic loss per share from continuing operations was USD 0.02 compared to USD 0.02 a year ago. Diluted loss per share from continuing operations was USD 0.02 compared to USD 0.02 a year ago.


ę S&P Capital IQ 2021
All news about ACERUS PHARMACEUTICALS CORPORATION
01/10Acerus Pharmaceuticals Details Commercial Agreement With Verity Pharmaceuticals to Prom..
MT
01/10Acerus Pharmaceuticals Announces Commercial Agreement With Verity Pharmaceuticals for t..
GL
01/10Acerus Pharmaceuticals Corporation Announces Commercial Agreement with Verity Pharmaceu..
CI
2021Acerus Announces Amendments to Loan Facilities
GL
2021Acerus Pharmaceuticals Corporation Announces Amendments to Loan Facilities
CI
2021Acerus Reports Fiscal Third Quarter Financial Results
GL
2021ACERUS : Q3 Earnings Snapshot
AQ
2021Acerus Pharmaceuticals Corporation Reports Earnings Results for the Third Quarter and N..
CI
2021Acerus to Report Q3-2021 Financial Results and Host Investor Call
AQ
2021Acerus Announces Participation in HC Wainwright Conference
GL
More news
Financials (USD)
Sales 2020 1,09 M - -
Net income 2020 -24,4 M - -
Net cash 2020 0,91 M - -
P/E ratio 2020 -1,05x
Yield 2020 -
Capitalization 43,0 M 43,0 M -
EV / Sales 2019 8,18x
EV / Sales 2020 43,7x
Nbr of Employees 10
Free-Float 8,63%
Chart ACERUS PHARMACEUTICALS CORPORATION
Duration : Period :
Acerus Pharmaceuticals Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ACERUS PHARMACEUTICALS CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Managers and Directors
Edward Gudaitis President, CEO & Non-Independent Director
Robert M. Motz Chief Financial Officer
Ian Orest Ihnatowycz Chairman
Christopher Sorli Chief Medical Officer
Stephen Robert Gregory Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ACERUS PHARMACEUTICALS CORPORATION40.00%43
JOHNSON & JOHNSON-2.62%438 538
ROCHE HOLDING AG-3.53%323 214
PFIZER, INC.-9.33%300 513
ABBVIE INC.-0.14%239 035
NOVO NORDISK A/S-12.67%223 059